PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2013.45.4.3252013454325-333Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung CancerJi-Won Kim, Youngil Koh, Dong-Wan Kim, Yong-Oon Ahn, Tae Min Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Banghttp://www.e-crt.org/upload/pdf/crt-45-325.pdf, http://www.e-crt.org/upload/pdf/crt-45-325.pdf
Clinical Lung Cancer10.3816/clc.2000.s.00720002S7-S10Chemotherapy Regimens in Advanced Non–Small-Cell Lung Cancer: Implications and Future PerspectivesChandra P. Belanihttps://api.elsevier.com/content/article/PII:S1525730411706428?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411706428?httpAccept=text/plain
Clinical Lung Cancer10.1016/s1525-7304(11)70791-419991129-30Four Platinum Based Doublets in Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Results of PS2 Patientshttps://api.elsevier.com/content/article/PII:S1525730411707914?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411707914?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2012.02.0022012135397Docetaxel Versus Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung CancerAthanasios Karampeazis, Vassilis Georgouliashttps://api.elsevier.com/content/article/PII:S1525730412000411?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730412000411?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2015.10.0032016172e25-e27Second-Line Treatment in Elderly Patients With Advanced Non–Small-Cell Lung CancerJacopo Giuliani, Andrea Bonettihttps://api.elsevier.com/content/article/PII:S1525730415002636?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730415002636?httpAccept=text/plain
Clinical Lung Cancer10.1016/s1525-7304(11)70857-9200895290Metronomic Chemotherapy in Patients with Advanced Non—Small-Cell Lung Cancer Associated with Long-Term SurvivalNick Chenhttps://api.elsevier.com/content/article/PII:S1525730411708579?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411708579?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(94)90385-91994111-2144Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: Implications for the design of future non-small-cell lung cancer combined modality trialshttps://api.elsevier.com/content/article/PII:0169500294903859?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0169500294903859?httpAccept=text/plain
Clinical Lung Cancer10.1016/s1525-7304(11)70751-320013142Commentary on “Photodynamic Therapy for Patients with Advanced Non–Small-Cell Carcinoma of the Lung”David Osthttps://api.elsevier.com/content/article/PII:S1525730411707513?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411707513?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2008.05.01520096311-9Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancerMartin Reck, Lucio Crinòhttps://api.elsevier.com/content/article/PII:S0169500208002961?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500208002961?httpAccept=text/plain
Clinical Lung Cancer10.3816/clc.2004.n.001200454209-213Management of Advanced Non–Small-Cell Lung Cancer in Patients with a Performance Status of 2Rogerio Lilenbaumhttps://api.elsevier.com/content/article/PII:S1525730411703400?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411703400?httpAccept=text/plain